August 9, 2019
Tagrisso showed improvement in overall survival with EGFR+ lung cancer patients (AstraZeneca)
AstraZeneca Tagrisso in a phase 3 trial, with previously-untreated patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) mutations, brought positive overall survival (OS) results.